Recent Company News

• 02:04 AM ET May 09, 2025
  

  Orexo chairman James Noble declines re-election (SEK 15.16, 0.00)

• 02:05 AM ET May 06, 2025
  

  Orexo reports Q1 EPS (SEK0.46) vs year-ago (SEK0.26) (SEK 14.50, 0.00)

• 02:17 AM ET Apr 10, 2025
  

  Orexo announces positive in-vivo proof-of-concept data for powder-based intranasal vaccine candidate formulated with AmorphOX technology (SEK 12.98, 0.00)

• 03:04 AM ET Mar 28, 2025
  

  Orexo releases sustainability report (SEK 15.44, 0.00)

• 04:04 AM ET Jan 10, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 02:18 AM ET Feb 06, 2025
  

  Orexo reports Q4 EPS (SEK3.37) vs FactSet (SEK1.64) [2 est, (SEK2.30)-(0.97)] (SEK 18.70, 0.00)

• 02:46 AM ET Jan 20, 2025
  

  Orexo converts future rights for OX-MPI to shares in Gesynta Pharma valued at SEK 19M (SEK 18.78, 0.00)

• 02:05 AM ET Jan 10, 2025
  

  Orexo announces positive topline results from the clinical study OX640-002 (SEK 18.28, 0.00)